Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1944 1
1947 2
1952 1
1953 1
1954 1
1956 2
1957 1
1958 1
1959 2
1962 1
1963 1
1964 5
1965 3
1966 2
1967 1
1968 1
1970 4
1974 2
1976 1
1978 2
1983 1
1984 3
1985 4
1986 4
1990 1
1992 4
1994 1
1995 4
1996 2
1997 8
1998 7
1999 2
2000 3
2001 7
2002 4
2003 4
2004 2
2005 4
2006 7
2007 5
2008 6
2009 2
2010 3
2011 8
2012 8
2013 5
2014 7
2015 8
2016 7
2017 11
2018 11
2019 19
2020 18
2021 10
Text availability
Article attribute
Article type
Publication date

Search Results

218 results
Results by year
Filters applied: . Clear all
Page 1
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group. Orkin C, et al. Among authors: martin ea. Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540. Clin Infect Dis. 2019. PMID: 30184165 Free PMC article. Clinical Trial.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. Molina JM, et al. Among authors: martin ea. Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15. Lancet HIV. 2020. PMID: 31740348 Clinical Trial.
Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.
Bercu JP, Galloway SM, Parris P, Teasdale A, Masuda-Herrera M, Dobo K, Heard P, Kenyon M, Nicolette J, Vock E, Ku W, Harvey J, White A, Glowienke S, Martin EA, Custer L, Jolly RA, Thybaud V. Bercu JP, et al. Among authors: martin ea. Regul Toxicol Pharmacol. 2018 Apr;94:172-182. doi: 10.1016/j.yrtph.2018.02.001. Epub 2018 Feb 9. Regul Toxicol Pharmacol. 2018. PMID: 29408293
Reply to Lanzafame et al.
Martin EA, Hwang C, Orkin C. Martin EA, et al. Clin Infect Dis. 2019 Oct 30;69(10):1832-1833. doi: 10.1093/cid/ciz229. Clin Infect Dis. 2019. PMID: 30891586 No abstract available.
Changes in weight and BMI with first-line doravirine-based therapy.
Orkin C, Elion R, Thompson M, Rockstroh JK, Alvarez Bognar F, Xu ZJ, Hwang C, Sklar P, Martin EA. Orkin C, et al. Among authors: martin ea. AIDS. 2021 Jan 1;35(1):91-99. doi: 10.1097/QAD.0000000000002725. AIDS. 2021. PMID: 33048879 Free PMC article.
Explicit and Implicit Affect and Judgment in Schizotypy.
Martin EA, Hua JPY, Straub KT, Kerns JG. Martin EA, et al. Front Psychol. 2019 Jul 1;10:1491. doi: 10.3389/fpsyg.2019.01491. eCollection 2019. Front Psychol. 2019. PMID: 31312158 Free PMC article.
218 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page